LabTurbo Biotech Corporation
LabTurbo Biotech Corporation engages in the research, manufacture, and sale of gene detection systems and kits in Taiwan, the United States, the Czech Republic, Spain, France, Israel, Singapore, the Philippines, and Malaysia. It serves hospitals. The company was founded in 2000 and is based in Taipei, Taiwan.
LabTurbo Biotech Corporation (7725) - Net Assets
Latest net assets as of June 2025: NT$1.21 Billion TWD
Based on the latest financial reports, LabTurbo Biotech Corporation (7725) has net assets worth NT$1.21 Billion TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.30 Billion) and total liabilities (NT$85.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.21 Billion |
| % of Total Assets | 93.42% |
| Annual Growth Rate | 7.38% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 25.05 |
LabTurbo Biotech Corporation - Net Assets Trend (2021–2024)
This chart illustrates how LabTurbo Biotech Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for LabTurbo Biotech Corporation (2021–2024)
The table below shows the annual net assets of LabTurbo Biotech Corporation from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.31 Billion | -1.67% |
| 2023-12-31 | NT$1.34 Billion | -13.06% |
| 2022-12-31 | NT$1.54 Billion | +44.84% |
| 2021-12-31 | NT$1.06 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to LabTurbo Biotech Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 33.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$638.85 Million | 48.64% |
| Common Stock | NT$483.27 Million | 36.79% |
| Other Components | NT$191.35 Million | 14.57% |
| Total Equity | NT$1.31 Billion | 100.00% |
LabTurbo Biotech Corporation Competitors by Market Cap
The table below lists competitors of LabTurbo Biotech Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Viet Nam Forestry Corporation JSC
VN:VIF
|
$6.39K |
|
Fideicomiso Irrevocable F/2061 FHipo
MX:FHIPO14
|
$6.40K |
|
AALR3F
SA:AALR3F
|
$6.40K |
|
FIRST PACIFIC (FPC.SG)
STU:FPC
|
$6.40K |
|
AGP Ltd
KAR:AGP
|
$6.39K |
|
Rajoo Engineers Limited
NSE:RAJOOENG
|
$6.39K |
|
TRINITY MIRROR
BE:MRR
|
$6.38K |
|
Bayn Group AB (publ)
MU:B39
|
$6.38K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LabTurbo Biotech Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,335,754,000 to 1,313,459,000, a change of -22,295,000 (-1.7%).
- Net income of 12,963,000 contributed positively to equity growth.
- Dividend payments of 24,163,000 reduced retained earnings.
- Share repurchases of 13,216,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$12.96 Million | +0.99% |
| Dividends Paid | NT$24.16 Million | -1.84% |
| Share Repurchases | NT$13.22 Million | -1.01% |
| Other Changes | NT$2.12 Million | +0.16% |
| Total Change | NT$- | -1.67% |
Book Value vs Market Value Analysis
This analysis compares LabTurbo Biotech Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.84x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.97x to 0.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$23.40 | NT$22.80 | x |
| 2022-12-31 | NT$31.32 | NT$22.80 | x |
| 2023-12-31 | NT$27.61 | NT$22.80 | x |
| 2024-12-31 | NT$27.15 | NT$22.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LabTurbo Biotech Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.99%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.76%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.06x
- Recent ROE (0.99%) is below the historical average (20.31%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 43.23% | 46.81% | 0.72x | 1.29x | NT$352.43 Million |
| 2022 | 41.84% | 47.89% | 0.76x | 1.16x | NT$489.15 Million |
| 2023 | -4.82% | -34.21% | 0.13x | 1.05x | NT$-197.92 Million |
| 2024 | 0.99% | 17.76% | 0.05x | 1.06x | NT$-118.38 Million |
Industry Comparison
This section compares LabTurbo Biotech Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LabTurbo Biotech Corporation (7725) | NT$1.21 Billion | 43.23% | 0.07x | $6.39K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |